Sobi submitted a rare drug application to Kineret to the US Food and Drug Administration (FDA), a drug for the treatment of early-onset multisystemic inflammatory diseases (NOMID).
Sobi stated that if it has obtained the pre-approved qualification, the validation is expected to reach 6-8 months.
The relevant data submitted this time was based on a previous clinical study.
Sobi’s CEO Geoffrey McDonough said: “This is a very promising drug for the treatment of infants, children and adults. We will work with the National Institutes of Health to push this rare drug as soon as possible. On the market."
Sobi stated that if it has obtained the pre-approved qualification, the validation is expected to reach 6-8 months.
The relevant data submitted this time was based on a previous clinical study.
Sobi’s CEO Geoffrey McDonough said: “This is a very promising drug for the treatment of infants, children and adults. We will work with the National Institutes of Health to push this rare drug as soon as possible. On the market."
Best Overbed Table,Best Medical Mattress,Medical Bed Accessories,Hospital Bed Accessories
Jiangyin Kaili Health-Care Equipment CO., LTD. , https://www.kailimed.com